Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Abstract Src homology-2 (SH2) domain-containing phosphatases (Shps) are a small, highly
conserved subfamily of protein-tyrosine phosphatases, members of which are present in …

Methylcytosine (m5C) is a posttranscriptional RNA modification participating in many critical
bioprocesses, but its functions in human cancer remain unclear. Here, by detecting the …

Although the use of ATP-competitive tyrosine kinase inhibitors of oncoprotein BCR-ABL1
has enabled durable responses in patients with chronic myeloid leukemia (CML), issues of …

Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown
remarkable clinical activity in patients with chronic myelogenous leukaemia (CML) …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

The tumour-suppressor phosphatase with tensin homology (PTEN) is the most important
negative regulator of the cell-survival signalling pathway initiated by phosphatidylinositol 3 …

Tyrosine kinases are involved in the pathogenesis of most cancers. However, few tyrosine
kinases have been shown to have a well-defined pathogenetic role in lymphomas. The …

As its role in tumor progression emerges, the PI3K/PKB (Akt) pathway presents an appealing
cancer therapeutic target. Recent studies have investigated the mechanisms underlying the …

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …